S-Dihydrodaidzein NEW
Price | $97 | $211 |
Package | 5mg | 20mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-14 |
Product Details
Product Name: S-Dihydrodaidzein | CAS No.: 879559-75-8 |
Purity: 99.20% | Supply Ability: 10g |
Release date: 2024/11/14 |
Product Introduction
Bioactivity
名稱 | S-Dihydrodaidzein |
描述 | S-Dihydrodaidzein ((3S)-7-hydroxy-3-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one) is an enantiomer of dihydrodaidzein which is involved in equol biosynthesis in a lactic acid bacterium, Lactococcus sp. strain. |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 60 mg/ml (234.15 mM) |
關鍵字 | S Dihydrodaidzein | inhibit | Inhibitor | SDihydrodaidzein | S-Dihydrodaidzein |
相關庫 | 天然多酚類化合物庫 | 黃酮類天然產物庫 | 中藥單體化合物庫 | 經典已知活性庫 | 植物來源化合物庫 | 天然產物庫 | 高通量篩選天然產物庫 | Ro5類藥天然產物庫 | 已知活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$38.00/10mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-06 | |
$1980.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
$10.00/1kg |
VIP2Y
|
GIHI CHEMICALS CO.,LIMITED
|
2024-09-11 | |
$97.00/5mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-14 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY